A. L. Bloom 2026-11-05
A. L. Bloom was a coagulation researcher who, with J. C. Giddings, investigated how activated Factor V promotes production of thrombin. Their 1975 study reconstructed the reaction using purified coagulation factors.[ref]
Factor-V activation by thrombin and its role in prothrombin conversion by J. C. Giddings and A. L. Bloom. Byline and Abstract: purified-factor experiments
Pretreating Factor V with trace amounts of thrombin increased the rate and yield of subsequent thrombin generation from prothrombin. The finding supported a positive feedback mechanism: product formation could enhance further product formation by activating a cofactor.[ref]
Anticoagulation Created 2026-10-31 Updated 2026-11-05
Reduction of blood-coagulation activity through interference with clotting mechanisms. It can limit formation or extension of thrombi; the body’s later removal of a clot is a different process from the drug’s immediate action.
Blood clot Created 2026-10-31 Updated 2026-11-05
A mass formed through coagulation and cellular interactions that can limit bleeding. A clot formed within an intact vessel can instead obstruct flow, connecting the same protective machinery with thrombosis.
Blood plasma Created 2026-10-31 Updated 2026-11-05
Blood plasma is the fluid component of blood in which cells are suspended. It contains water, proteins and dissolved substances, including components of coagulation. Serum is obtained after clotting and therefore is not compositionally identical to plasma.
Coagulation factor Created 2026-10-31 Updated 2026-11-05
A coagulation factor participates in the regulated reactions leading to formation of a clot. Different factors have different activation and interaction roles. Their concentration and functional activity are distinct measurements, and coagulation is only one part of haemostasis.
Factor V 2026-11-05
Factor V is a coagulation factor whose activated form, factor Va, is a protein cofactor in the prothrombinase complex. Limited proteolysis, including cleavage by thrombin, converts Factor V into the more active cofactor. In the assembled complex, factor Xa performs the cleavage of prothrombin to thrombin; factor Va helps the reaction occur efficiently on a phospholipid surface in the presence of calcium ions.[ref]
Factor-V activation by thrombin and its role in prothrombin conversion by J. C. Giddings and A. L. Bloom. Abstract: thrombin pretreatment and reconstitution from purified components
The distinction between precursor and activated cofactor matters experimentally. Investigators mixed purified coagulation factors, separated the products by gel chromatography, and identified components with specific antibodies. Pretreating Factor V with small amounts of thrombin increased the rate and yield of subsequent thrombin generation. A little product could therefore promote production of more product: a positive feedback mechanism within coagulation.[ref]
Factor-V activation by thrombin and its role in prothrombin conversion by J. C. Giddings and A. L. Bloom. Abstract: column fractions, immunological analysis, and kinetic experiments
Factor X 2026-11-05
Factor X is the zymogen of factor Xa, a serine protease involved in coagulation. Limited proteolysis activates Factor X; the resulting factor Xa cleaves prothrombin to form thrombin. Efficient membrane-associated activation uses the prothrombinase complex, containing factor Xa, factor Va, calcium ions and phospholipids.[ref]
Coagulation factor Xa EC 3.4.21.6 in IUBMB Enzyme Nomenclature. Accepted name, reaction and comments: precursor activation and prothrombin conversion
The human protein contains a heavy chain and a light chain joined by disulfide bonds. This chain structure and activation are different distinctions: having two linked chains does not by itself mean that the zymogen has become factor Xa.[ref]
Coagulation factor Xa EC 3.4.21.6 in IUBMB Enzyme Nomenclature. Comments: precursor processing and limited proteolysis
For example, a preparation can contain abundant Factor X yet require an activating cleavage before efficiently supporting thrombin production. Conversely, detecting factor Xa activity reports an activated enzyme, not merely the presence of its precursor. Purified-component experiments establish the downstream reaction independently of a whole blood clot, allowing the catalytic role of factor Xa to be distinguished from the assisting role of factor Va.[ref]
Factor-V activation by thrombin and its role in prothrombin conversion by J. C. Giddings and A. L. Bloom. Abstract: prothrombin conversion by the reconstituted complex
Factor Xa 2026-11-05
Factor Xa is the activated serine protease derived from Factor X by limited proteolysis. It catalyses cleavage of prothrombin to generate thrombin, an important activation step in coagulation. Efficient conversion is organized by factor Va, calcium and phospholipids.[ref]
Coagulation factor Xa EC 3.4.21.6 in IUBMB Enzyme Nomenclature. Reaction and comments: precursor, activation and prothrombin conversion
Purified-component experiments varied the phospholipid surface and the presence of factor Va, showing that apparent kinetic parameters depend on how the components assemble. The same amount of factor Xa can therefore produce different reaction rates in different surroundings.[ref]
For an invented catalytic accounting example, 1 nmol of active factor Xa generates 100 nmol of activated product during an interval. That is 100 product molecules per initial enzyme molecule, demonstrating catalytic reuse rather than one-to-one consumption. The value is not a measured turnover number: a true rate constant requires a specified time, substrate availability and activation pathway.
Fibrinogen 2026-11-05
Fibrinogen is a soluble blood plasma protein that supplies the building material for fibrin during coagulation. Thrombin cleaves small fibrinopeptides from fibrinogen, exposing sites that allow the resulting fibrin units to associate. The cleavage is a chemical trigger for assembly; forming the network also requires interactions between different protein molecules.[ref]
Thrombin EC 3.4.21.5 in IUBMB Enzyme Nomenclature. Reaction and comments: fibrinopeptide release and fibrin formation
A single-molecule experiment used optical tweezers to bring prepared protein partners together and measure their separation forces. Exposing the “A” binding knobs in fibrin produced strong specific interactions with complementary sites in fibrinogen or its end fragment. A competing peptide that mimicked the exposed knob suppressed those interactions, providing a control for binding-site specificity.[ref]
Haematology Created 2026-10-31 Updated 2026-11-05
Haemostasis Created 2026-10-31 Updated 2026-11-05
Haemostasis limits blood loss after vascular injury through interacting vascular, platelet and coagulation processes. Forming a stable local seal and maintaining flow elsewhere are competing constraints. A measured clotting reaction therefore represents one component rather than the entire physiological response.
Hypercoagulability Created 2026-10-31 Updated 2026-11-05
A state in which the coagulation system is more prone to generate clots. It is one contributor to thrombosis, alongside disturbances in flow and vascular surfaces.
J. C. Giddings 2026-11-05
J. C. Giddings is the coagulation researcher who coauthored the 1975 study of Factor V activation and prothrombin conversion with A. L. Bloom. The work investigated both assembly of reaction components and production of thrombin.[ref]
Gel chromatography separated the preparations, and specific antibodies helped identify components in the resulting fractions. Combined with kinetic measurements, these experiments supported a functional assembly involving phospholipids, Factor V, factor Xa and calcium ions.[ref]
Factor-V activation by thrombin and its role in prothrombin conversion by J. C. Giddings and A. L. Bloom. Abstract: Sephadex chromatography, immunological analysis and thrombin-generation tests
This illustrates two complementary questions: which molecules associate, and does their association support the expected reaction? Component identification addresses composition; an activity assay addresses function. Using both provides a stronger explanation than either separation or product measurement alone.
Ligature Created 2026-10-31 Updated 2026-11-05
A thread or similar material tied around a structure, commonly to secure a vessel or tissue pedicle. Mechanical occlusion can control local flow, distinguishing the device from a medicine that changes coagulation throughout the blood circulation.
Classify the bleeding by anatomical source and by its relation to pregnancy, childbirth and menstruation; treatment must address that source. The amount of visible genital haemorrhage does not measure all the loss: a ruptured ectopic pregnancy or concealed placental abruption can cause major internal blood loss. Initial assessment of severe bleeding concerns the circulation, anaemia and the need for resuscitation while the cause is established. Bleeding from the urethra or rectum must first be distinguished from genital bleeding.
Local sources outside the uterine cavity. The vulva and vagina may bleed from lacerations after childbirth or other trauma, an inflamed lesion, a foreign body, a vascular lesion or cancer. Examination localizes the loss; treatment is local compression and repair of a significant laceration, removal of the foreign body, cause-directed treatment of infection, or specialist management of the lesion. A cervical polyp, cervical ectropion, cervicitis or cervical cancer can cause bleeding from the cervix, often noticed between periods or after intercourse. A suitable polyp can be removed and examined; inflammation requires its cause to be established, while a suspicious lesion requires diagnostic assessment rather than indiscriminate cauterization. After menopause, thin, fragile vulvovaginal tissues can also bleed; this does not remove the need to investigate a suspicious lesion. These are different conditions, not one disease called “uterine haemorrhage”. [ref]
Vaginal Bleeding by Merck Manual. Etiology, examination and cause-directed treatment of vulvar, vaginal and cervical bleeding
Bleeding from the endometrium. Heavy or irregular menstruation may accompany ovulatory dysfunction, uterine fibroids, endometrial polyps, adenomyosis, a coagulopathy, medication effects or endometrial cancer. Modern assessment includes the menstrual and drug history, a full blood count, and selected ultrasound, hysteroscopy or tissue sampling according to the suspected cause. Where appropriate, menstrual bleeding can be reduced with tranexamic acid or hormonal treatment; an intracavitary polyp or uterine fibroid may instead need targeted removal. Persistent postmenopausal bleeding must not simply be treated as an ordinary period. [ref]
Heavy menstrual bleeding by NICE. NG88 §§1.2–1.5: assessment, blood count, selected investigation and medical or surgical treatment
Early pregnancy. A miscarriage may bleed while pregnancy tissue separates or remains in the uterus. In a stable, confirmed case, expectant, medical or surgical management may be appropriate; heavy continuing loss or infection changes the urgency. Ectopic pregnancy requires a separate plan: selected stable cases may be monitored or treated medically, but rupture with haemorrhagic collapse requires urgent operative control, not treatment of the vagina as though it were the principal source. A hydatidiform mole is another pregnancy-related source of abnormal bleeding; current management includes removal by suction evacuation and subsequent human chorionic gonadotropin surveillance for persistent disease. [ref]
Gestational Trophoblastic Disease Treatment by NCI. Hydatidiform moles: bleeding, evacuation and biochemical follow-up
[ref]Bleeding During Pregnancy by ACOG. Early pregnancy loss, ectopic pregnancy and the distinction between vaginal and internal bleeding
[ref]Ectopic pregnancy and miscarriage by NICE. NG126, management of tubal ectopic pregnancy and diagnostic precautions
Later pregnancy and labour. Placenta praevia commonly produces relatively painless bleeding, whereas placental abruption more often causes pain and uterine tenderness; these are useful patterns, not infallible rules. Management depends on the mother's circulation, the fetus, the placental lesion and the stage of pregnancy, with urgent delivery when required. A blind digital cervical examination is inappropriate before a possible placenta praevia has been excluded. Ruptured vasa praevia causes fetal rather than maternal bleeding and demands a different interpretation. A small blood-stained mucous “show” during cervical change is not equivalent to these pathological losses. [ref]
Antepartum Haemorrhage by the Royal College of Obstetricians and Gynaecologists. Green-top 63, history, examination and management; exclusion of placenta praevia before digital examination
[ref]After delivery. The principal categories are failure of uterine contraction, retained placental tissue, trauma and disordered coagulation. For uterine atony, the aim is to restore contraction with uterine massage and an appropriate uterotonic. Retained tissue, a genital laceration or uterine inversion requires correction of that particular cause; a coagulopathy requires haemostatic support. With placenta accreta spectrum, attempted forcible separation can provoke severe haemorrhage. Current care combines resuscitation with cause-directed measures, and can require tranexamic acid, balloon tamponade, embolisation or surgery when initial measures fail. Later postpartum bleeding also raises retained tissue and endometritis. [ref]
Heavy bleeding after birth by RCOG. Causes and treatment, including retained placenta, uterine contraction, trauma and escalation
The 1865 distinction. An answer of the period could distinguish menstrual loss, local lesions, pregnancy-related haemorrhage and post-delivery failure of contraction through the history and physical examination. Compression, local plugging, removal of an accessible lesion and obstetric intervention were among the available approaches; their use was debated. The 1864 discussion of placenta praevia documents such disagreement. Modern imaging, blood banking, the present drug regimens and current operative pathways must not be attributed to that practice. Nor should historical astringents or depletion be substituted for identifying the source. [ref]
Midwifery in the Edinburgh Medical Journal (September 1864). pp. 262–268, discussion of placenta praevia and competing methods of management
The strongest evidence is a genuine reaction of living tissue, particularly established inflammation or wound healing; bleeding, gaping and a clot are supporting observations, not individually decisive proofs.
Examine the whole body before disturbing the wound, recording its situation, dimensions, margins and relation to damaged blood vessels. Then expose the wound track by careful dissection. An injury received while the blood circulation was active may show substantial hemorrhage, blood infiltrating the surrounding tissue, and adherent blood clots. Infiltration is more informative than loose blood merely lying on the surface: serial cuts can show whether blood has penetrated the tissue rather than simply coated it.
The interval of survival changes what can reasonably be expected. If the person survived long enough, surrounding inflammation, cellular reaction, formation of granulation tissue, or an established scar is evidence of a process that began during life. Such findings can make the conclusion much stronger than the appearance of a fresh cut. They do not furnish a universal clock: wound healing varies with site, severity, health and environment.
A post-mortem cut will often have relatively pale margins and little infiltration, although it can gape because skin and other tissues are elastic. Blood may still escape from a recently dead body, particularly from dependent or congested parts, and coagulation can occur around the time of death. Livor mortis can resemble bruising, while drying and putrefaction alter colour and consistency. A body moved, compressed or subjected to attempts at resuscitation presents further opportunities for artefact. Therefore neither “it bled” nor “the edges retracted” establishes that the wound was inflicted during life.
For modern corroboration, sample the margin, underlying tissue and an uninjured comparison site for histology, interpreting inflammation and other markers in the context of the whole examination. A primary study of decomposed forensic cases illustrates the use of immunohistochemistry while explicitly warning that extravasated red blood cells alone do not reliably establish wound vitality.[ref]
Wound Vitality in Decomposed Bodies: New Frontiers Through Immunohistochemistry. 2021, Introduction and Discussion: ante-mortem injuries, decomposition and limitations of erythrocyte extravasation
Consequently, a rapidly fatal wound may be impossible to distinguish confidently from one inflicted immediately after death by gross aspect alone. Absence of developed inflammation is expected when survival was extremely brief; it is not proof of post-mortem injury. The answer should express the degree of support, rather than force an unwarranted yes-or-no conclusion.
Severe haemoptysis in a person described historically as “phthisical” requires immediate attention to breathing and circulatory danger; the treatment of chronic wasting cannot wait in place of control of the acute bleeding. The historical label suggests pulmonary tuberculosis, but does not itself prove that diagnosis or identify the bleeding vessel.
In period terms, the sensible supportive aims were quiet, reduced exertion and observation of the blood loss and general condition. The intent was to avoid provoking further cough or dislodging a clot, while preserving the person's remaining strength. A depleted person with chronic wasting was a poor candidate for reflex general bloodletting. The historical pharmacological literature included astringents, mineral salts and external cold, but the mere sequence “remedy administered, bleeding stopped” could not establish efficacy: haemoptysis often varied or stopped temporarily on its own.
This uncertainty was recognized before the examination. An 1862 discussion lists astringents such as lead acetate, emetic drugs and external ice among competing treatments, and questions the evidential value of events following their use. It also records opposing fashions of severe dietary restriction and frequent feeding with stimulants.[ref]
On the Treatment of Tubercular Hemoptysis by William Brinton. 1862, pp. 553–557, opening discussion of competing specifics and the limitations of apparent therapeutic success
The same author advocated a digitalis preparation with close pulse observation for severe attacks, hoping to influence the circulation; he emphasized its dangers. This is a period proposal, not modern emergency treatment. The historical explanation is why rest and supposed haemostatic remedies were attempted, not a claim that they reliably closed a ruptured vessel. No toxic nineteenth-century mixture is recommended here.Modern correction: life-threatening haemoptysis is an airway emergency, often killing through obstruction and loss of gas exchange. Its severity depends on respiratory and circulatory effects, not just the estimated volume in a basin. Obtain emergency specialist support, maintain oxygenation and protect the unaffected lung; when the bleeding side is known, positioning that side down can limit contamination of the other side. Secure suitable intravenous access, assess haemoglobin and coagulation, prepare for needed blood transfusion and correct important coagulopathy. In unstable ongoing bleeding, securing the airway and bronchoscopy can take precedence over transport for imaging.[ref]
Society of Chest Imaging and Interventions Consensus Guidelines for the Interventional Radiology Management of Hemoptysis. 2023, initial management of life-threatening hemoptysis; airway isolation, positioning and haemodynamic stabilization
Once sufficiently stable, computed tomography angiography helps locate the source and plan treatment. Bronchial artery embolisation is a principal means of controlling severe or recurrent haemoptysis from abnormal systemic vessels. Bronchoscopy can assist localization and temporary control; selected lesions or failed endovascular control may require surgery. Do not assume every tuberculosis-associated haemorrhage comes from the same vascular bed. The intervention must match the demonstrated source. Modern management also treats the underlying disease; stopping bleeding alone does not cure pulmonary tuberculosis.[ref]
CIRSE Standards of Practice on Bronchial Artery Embolisation. 2022, Table 1; indications; diagnostic and treatment pathways
Suspected active pulmonary tuberculosis warrants appropriate respiratory infection-control measures, diagnostic sampling when safe and a susceptibility-informed multidrug antibiotic regimen once the diagnosis and treatment plan are established.[ref]Treatment for Drug-Susceptible Tuberculosis Disease by CDC. Choice of regimen; drug susceptibility, coexisting conditions and interactions
Quiet surroundings can still help, but neither ice nor a historical astringent substitutes for these measures. Plasma protein Created 2026-10-31 Updated 2026-11-05
A plasma protein is a protein present in blood plasma. Transport, immune functions, coagulation and osmotic effects are among their different roles. Total protein concentration does not specify the amount or activity of any one component.
Postpartum haemorrhage Created 2026-10-31 Updated 2026-11-05
Excessive bleeding after childbirth. Uterine contraction, tissue retention, trauma and coagulation abnormalities provide different mechanisms; the syndrome is defined clinically rather than by one cause.[ref]
Prothrombin 2026-11-05
Prothrombin is the zymogen, or inactive precursor, from which the protease thrombin is generated during coagulation. Controlled proteolysis converts a circulating precursor into an active enzyme. factor Xa catalyses activation, with factor Va and a phospholipid surface greatly affecting the reaction's efficiency.[ref]
A purified bovine system varied both vesicle composition and the presence of factor Va. With one defined mixture, the apparent Michaelis constant for prothrombin was without factor Va and with it, a 55-fold difference. The result connects the enzyme reaction to assembly on a phospholipid surface, rather than treating the surrounding lipids as inert solvent.[ref]
Kinetic studies of prothrombin activation: effect of factor Va and phospholipids on formation of the enzyme-substrate complex by J. L. van Rijn and others. Abstract: vesicles containing 20 mole percent phosphatidylglycerol and 80 mole percent phosphatidylcholine
An apparent Michaelis constant in this assembled system summarizes several interacting steps; it need not equal a single molecular binding constant. In an activation assay, detecting the newly generated thrombin's activity also differs from merely measuring how much prothrombin remains.